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Purpose: Memantine has been proven to be effective in patients with moderate to severe Alzheimer's
disease (AD) and has been available in China since 2006. However, antidementia therapy is not widely
used in patients with AD in our region. Therefore, we surveyed the situation of memantine utilization in
our hospital.
Methods: Data on dementia patients who received memantine were obtained from the database of The
First Afﬁliated Hospital of Chongqing Medical University between January 2011 and September 2012.
Data were collected by face-to-face interview and/or telephone interview by direct questions on
memantine dosage, efﬁcacy, adverse events (AEs), Clinical Global Impression Change (CGI-C) score, and
the reasons for drug withdrawal, and the results were summarized.
Results: A total of 118 patients were selected, of which 88 patients completed this study. Memantine was
prescribed for patients with dementia and the status of its application is as follows: 32 patients were
treated with the drug for <1 month; 15 patients were treated between 1 month and 6 months; 41 pa-
tients were treated for >6 months. The reasons for memantine withdrawal included the lack of
knowledge about dementia care, economic problems, lack of satisfaction with efﬁcacy, and obvious side
effects. The improvement of the clinical condition was found in patients treated with memantine for >6
months compared with the patients treated with memantine for <1 month (CGI-C score, 3.80 vs. 4.72,
p < 0.05). Of the 88 patients, four (4.54%) had AEs.
Conclusion: Prescription of memantine is reasonable in our region. However, medication compliance is
not optimal. Thus, public should be educated about dementia and about the available medications.
Copyright © 2015, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Dementia is a common syndrome in elderly people worldwide.
According to the World Health Organization report, dementia had
affected approximately 35.6 million people in 2010, and this
number is estimated to double in the next two decades. In China,
the estimated prevalence of Alzheimer's disease (AD) is 4.8% in four
major cities (Beijing, Xi'an, Shanghai and Chengdu). However, only
26.9% of patients with dementia received a dementia diagnosis,
with only 21.3% being recommended to take antidementiahe First Afﬁliated Hospital of Chon
erms of the Creative Commons At
ribution, and reproduction in any
linical Gerontology & Geriatrics. Pmedication.1,2 Therefore, it is a big challenge to improve the diag-
nosis of dementia and antidementia treatment in China. The cur-
rent antidementia medications, including cholinesterase inhibitors
(ChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists,
are available in the Chinese market.
Memantine is a glutamatergic NMDA receptor antagonist for the
treatment of AD. It was ﬁrst launched by Merz, in Frankfurt, Ger-
many, in 1982 for treating various central nervous system disor-
ders.3 It has been approved for treating patients with moderate to
severe AD in Europe in February 2002, and in the United States bygqing Medical University, Youyi Road, Yuzhong District, Chongqing 400016, China.
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 1
Characteristics of patients included in this study (n ¼ 88).
Characteristics Total
Mean age (y) 78.9 ± 8.96
Sex
Female 42 (47.7)
Male 46 (52.3)
Dementia types
Alzheimer's disease 49 (55.9)
Vascular dementia 17 (19.3)
Mixed dementia 13 (15.9)
Parkinson's disease with dementia 5 (5.6)
Frontotemporal dementia 1 (1.1)
Alcohol-related dementia 1 (1.1)
Depression 1 (1.1)
Psychotropic prescriptions
Hypnotics 7 (8.0)
Antipsychotics 11 (12.5)
Antidepressants 8 (9.1)
Data are presented as n (%) or mean ± SD.
Table 2
Reasons for memantine withdrawal (n ¼ 47).
Reasons No. of patients
Inaccessibility of medication 2
Economic burden 7
Unaware that memantine needs to be taken for a long period 13
Obvious side effects 1
Lack of care 2
Consideration about no signiﬁcant effect and advanced age 12
Doctors' recommendations 9
Marked degradation 1
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2003.4 Moreover, memantine is also prescribed for patients with
vascular dementia (VaD), AD mixed VaD, dementia with Lewy
bodies, Parkinson's disease with dementia (PDD), frontotemporal
lobar dementia (FLD) and alcohol-related dementia.5e10 In China,
memantine has been on the market since 2006, and is one of
medicines covered by medical insurance since 2010 in Chongqing,
Southwest China. Since then, memantine has been frequently used
in our region. However, dementia is not in the list of special dis-
eases, add therefore, patients have to pay for the treatment (i.e., not
covered by insurance). However, the out-of-pocket expenses can be
reimbursed during hospitalization.
In clinical practice, we found that the application of memantine
has not always been consistent, and patients sometimes have poor
compliance. The underlying reasons are unknown. Therefore, the
current situation of memantine administration needs to be inves-
tigated in our region. The present survey aims to understand the
rationality of memantine, the reasons for drug withdrawal, treat-
ment efﬁcacy, and side effects of the drug. This will be helpful for
improving the use of memantine.
2. Methods
2.1. Patients
Patients with memantine prescriptions were screened from
January 2011 to September 2012, and the data were taken from the
medicine database of The First Afﬁliated Hospital of Chongqing
Medical University, Chongqing, China. This is a retrospective study.
All screened patients were included only if they or their family
members accepted our survey. The written informed consent was
signed by the patients. This study was approved by the Ethical
Committee of The First Afﬁliated Hospital of Chongqing Medical
University on Human Research.
2.2. Data collection
Data were collected by face-to-face interview and/or telephone
interview by direct questions and then summarizing the results
from the whole interview. The surveyed patient information
included age, sex, diagnosis, dementia type, severity of dementia
symptoms, Mini-Mental State Examination (MMSE), if available,
memantine dosage, combined drugs (psychotropics, ChEI), adverse
events (AEs), and the reasons for drug withdrawal. Moreover, the
Clinical Global Impression Change (CGI-C) scores were evaluated to
determine whether there are improvements in symptoms in these
patients. The CGI-C scores ranged from 1 to 7. Score 1 indicated very
much improved, Score 2 indicated much improved, Score 3 indi-
cated minimally improved, Score 4 indicated a stable state, Score 5
indicated minimally worse, Score 6 indicated much worse, and
Score 7 indicated very much worse.
2.3. Statistical analysis
All data were expressed as mean ± standard deviation and the
analysis was performed using SPSS statistics 17.0 (SPSS Inc., Chi-
cago, IL, USA). The differences in the CGI-C scores were evaluated
with the KruskaleWallis and ManneWhitney U tests. A p value
<0.05 was taken to be signiﬁcant.
3. Results
We sampled 118 patients treated with memantine. Eighty-eight
patients completed this study; 21 patients were lost to follow-up,
and nine patients died.The average age of the 88 patients (42 male patients and 46
female patients)was 78.9± 8.96 years. The patientswere diagnosed
withmoderate to severe dementia. The mean score of MMSEwas 9.
Memantinewas used in different types of dementia, including in 49
patients with AD, 17 patients with VaD, 13 patients with mixed
dementia, ﬁve patients with PDD, one patient with frontotemporal
dementia, one patient with alcohol-related dementia, and one pa-
tient with depression. Psychotropic drugs were used in 26 patients
(Table 1). Memantine was prescribed as a monotherapy for 56
(63.6%) patients, and 32 (36.4%) patients were treated with done-
pezil, along with memantine. We divided the patients into the
following three groups based on the period ofmemantine usage:<1
month (Group 1), 1e6 months (Group 2), >6 months (Group 3).
Thirty-two patients were treated with memantine for <1month, 15
patients were treated with memantine between 1 month and 6
months, and 41 patients were treated with memantine for >6
months. There were no signiﬁcant differences in the CGI-C scores
between memantine monotherapy and dual therapy (p ¼ 0.553).
Themean CGI-C scorewas 4.72 in Group 1, 3.93 in Group 2, and 3.80
in Group 3. Therewere no signiﬁcant statistical differences between
Group 2 and Group 3 (p > 0.99). Signiﬁcant statistical differences
were detected between Group 1 and Group 3 (p ¼ 0.001), and be-
tween Group 1 and Group 2 (p ¼ 0.004).
Of the 56 patients whowere treated for >1month, the dosage of
memantine (20 mg/d) was maintained in 54 patients using the
titration method. For the remaining two patients, the dosage was
adjusted to 5 mg/d and 10 mg/d, respectively.
The detailed reasons for drug withdrawal included economic
burden, inconvenience in purchasing memantine, patients' un-
awareness that this drug needs to be taken for a long period, pa-
tients' doubts regarding the efﬁcacy of this drug, doctor's advice,
and marked degradation (Table 2). Finally, we summarized these
responses into four reasons. Forty-seven patients (53.4%) dis-
continued memantine for the following reasons: economic
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dementia in 17 patients, obvious AEs in one patient, unsatisfactory
efﬁcacy in 13 patients, and the doctors' recommendation in nine
patients with very severe stage of dementia.
Of the 88 patients, four (4.54%) had AEs, which included fatigue,
somnolence, agitation, and increased libido. Only one patient suf-
fered from the severe side effects (agitation), and thus treatment
with memantine was discontinued.
4. Discussion
Our present study indicates that the incidence of memantine
withdrawal is high with multiple reasons. Memantine adminis-
tration at a dose of 20 mg/d is safe and was tolerated by patients in
this study.
Our study has shown that there are several reasons for with-
drawal from the patients' point of view, and they are as follows.
First, caregivers have limited education regarding the illness or the
need for medications. In our survey, some caregivers cannot
differentiate the symptoms of dementia from normal aging, and
other caregivers had the misunderstanding that only short-term
applications of antidementia drugs are needed. These indicate
that caregivers have a lack of medication knowledge or the lack of
disease knowledge needed to comprehend what is appropriate for
the treatment of dementia. Second, caregivers have a limited faith
in antidementia medications. Memantine was discontinued in
some patients due to complaints by the caregiver regarding the
inefﬁcacy of the drug. However, caregivers do not know that the
stabilization of dementia is considered an effective treatment when
patients have been diagnosed with advanced stage dementia. Thus,
the efﬁcacy often falls short of their expectations, and the patients
and their caregivers discontinue the antidementia drugs to seek
other therapies, such as Chinese medicine.11 Third, memantine was
discontinued because of obvious side effects. In our study, only four
cases had the AEs, including fatigue, somnolence, agitation,
increased libido. Treatment was discontinued in one patient due to
agitation. Lastly, families considered the issues of cost and beneﬁt.
These factors included family structure, economic status, living
environment, and symptoms of the disease. Seven patients stopped
memantine, and in two patients, the dosage was cut in half due to
the high cost of the medication. Besides those reasons, the low
salary rate and poor insurance coverage also contributed to the
nonadherence.
In addition, physician-related factors also contributed to with-
drawal of memantine. It has been reported that inadequate
communication between specialists, hospital staff, primary-care
physicians, and consultants also contribute to medication errors
and potentially avoidable hospital readmissions.12 Moreover,
invalid communications between primary-care physicians and
patients affect the patients' understanding of his or her disease,
which contributes to the potential complications, and stresses the
importance of medication compliance.13 In our survey, some pa-
tients and caregivers did not have enough knowledge about de-
mentia. In addition, they did not understand the treatment strategy
due to inadequate communication with their physicians.
Memantine has been approved for the treatment of moderate to
severe AD in China. Moreover, clinical studies suggest that mem-
antine may be effective for alleviation of symptoms in a number of
dementia subtypes such as VaD, AD mixed VaD, PDD, alcohol-
related dementia, and FLD.14 Memantine had a signiﬁcantly posi-
tive effect on the cognitive performance and behavioral symptoms
of VaD patients in a double-blind, placebo-controlled, multicenter
study.6,15 In addition, according to a review of ﬁve clinical studies on
PDD patients treated with memantine, cognition and global func-
tions were signiﬁcantly improved, and psychiatric symptoms werealleviated.16 A 26-week noncontrolled, open-labeled, prospective
study showed that memantine could signiﬁcantly improve the
neuropsychiatric inventory score in frontotemporal dementia pa-
tients, particularly in the alleviation of indifference, irritation, and
anxiety.14 Mixed dementia should be treated as AD.10 In an open-
labeled study, patients with alcohol-related dementia were
treated with 20 mg/d memantine for 12 weeks and showed
improvement in global cognition, quality of life, and behavioral
symptoms.9 Therefore, when the diagnosis of the dementia subtype
cannot be clearly made, or when there are no clear therapeutic
options, memantine may be the simple and safe option.14 Our
survey also presented the application of memantine in various
dementia subtypes and showed a safe proﬁle.
In clinical practice, it is suggested that persistent treatment with
antidementia medications slowed the progression of AD.17,18 Our
ﬁnding also supports this notion because the CGI-C scores are
generally better in patients with long-term (>6 months) treatment
with memantine, although psychotropic drugs could interfere with
the CGI-C evaluation.19
In addition, memantine treatment was heterogeneous in the
present study because a large number of patients only took mem-
antine for <1 month, and some patients were treated with done-
pezil in addition to memantine. However, our heterogeneous data
reﬂect the current status of antidementia drugs used in our region.
This phenomenon conﬁrms that the treatment rate and awareness
rate of dementia are low. Therefore, we need more mental health
education for patients and their families.
There were several limitations in this study. First, the sample
size was limited because memantine has only been available in top
general hospitals in Chongqing for the past several years. Second,
the different beneﬁts between memantine monotherapy and the
combination therapy with ChEI were not obtained due to sample-
size limitation. Third, because this is a retrospective investigation,
the efﬁcacy on the cognition of memantine has not been evaluated.
A further prospective study will be performed to identify the long-
term efﬁcacy of memantine on patient cognition and the progres-
sion of dementia in patients.
In conclusion, our study indicated that the rate of drug with-
drawal was high. Patient health education on dementia and its
treatment should be regularly provided to the general public. We
highlighted the need for dementia education to the general public
to achieve early diagnosis, early treatment, and to improve medi-
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